Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline

Table 2 Values of neurodegenerative markers by amyloid-β/white matter hyperintensities groups

Neurodegeneration markers	Aβ − WMH− (n = 140)	Aβ − WMH+ (n = 39)	Aβ + WMH− (n = 63)	Aβ + WMH+ (n = 29)
MTA score	1.2 (1.2)^a,b,c	2.6 (1.6)^c,d	2.1 (1.6)^c,d	3.4 (1.8)^a,b,d
MTA abnormal, n	62 (45)^a,b,c	32 (82)^d	41 (67)^c,d	26 (93)^b,d
p-tau, pg/ml	54.5 (27.7)^b	63.2 (29.3)	77.0 (56.3)^d	65.2 (38.2)
p-tau abnormal, n	53 (38)^b	22 (58)	45 (71)^d	15 (52)
t-tau, pg/ml	314.7 (202.0)^a,b,c	438.4 (248.0)^d	499.3 (413.8)^d	426.2 (275.2)^d
t-tau abnormal, n	36 (26)^a,b,c	20 (53)^d	36 (57)^d	14 (48)^d

Abbreviations: Aβ Amyloid-β, MTA Medial temporal lobe atrophy, p-tau Phosphorylated tau, T-tau Total tau, WMH White matter hyperintensities
Results are mean (SD) and number (%). All analyses were adjusted for study, baseline diagnosis, and demographics
^a p < 0.05 compared to Aβ - WMH-
^b p < 0.05 compared to Aβ - WMH+
^c p < 0.05 compared to Aβ + WMH-
^d p < 0.05 compared to Aβ + WMH+

ISSN: 1758-9193